Year - 2012 Blog

Durata Therapeutics In.c to Move to CT, 80 New Jobs Created

Governor Dannel P. Malloy today announced the state will provide up to $2.25 million in grants to Durata Therapeutics

Governor Dannel P. Malloy today announced the state will provide up to $2.25 million in grants to Durata Therapeutics, Inc. to support the relocation of its research and development, clinical, and regulatory operations from New Jersey to Branford. The company, whose headquarters are in Chicago, Illinois, will create up to 80 new, full-time jobs in Connecticut. “The goal of Bioscience Connecticut is twofold – creating good paying jobs with good benefits for residents in an industry that is poised for growth,” said Governor Malloy.

Celegen Corporation's Revlimid Combo Fails as Prostate Cancer Therapy

Adding lenalidomide (Revlimid) to the chemotherapy regimen led to greater toxicity and worse survival in patients

Celegen Corporation's Revlimid Combo Fails as Prostate Cancer Therapy Adding lenalidomide (Revlimid) to the chemotherapy regimen led to greater toxicity and worse survival in patients with untreated castration-resistant prostate cancer (CRPC), results of a large international trial showed. Men randomized to a regimen of lenalidomide, docetaxel, and prednisone, had a 53% increased mortality hazard, a 32% greater hazard for progression, and significantly higher rates of neutropenia, febrile neutropenia, and multiple non-hematologic adverse events.

Pages